IP Library Granted Patent US 12,076,448
Granted Patent B2
US 12,076,448 · App. 17/407,026 · Granted Sep 3, 2024

Hemostatic devices

Inventors: Raymond J. Huey (Orange, CT); Denny Lo (Bethlehem, CT); Daniel J. Burns (Stratford, CT); Giacomo Basadonna (Haddam, CT); Francis X. Hursey (West Hartford, CT)
Assignee: TELEFLEX LIFE SCIENCES II LLC
A61L15/44A61F13/00012A61F13/00063A61L15/18A61L15/28A61L15/425A61L2300/404A61L2300/406A61L2400/04A61L2400/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,076,448
App. No.
17/407,026
Granted
Sep 3, 2024
Kind
B2
Abstract

A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Claims (34)

1. A hemostatic device comprising:

a flexible absorbent substrate comprising cloth, gauze, mesh, or strands;

a hemostatic aluminum silicate material positioned on or in the substrate in a region configured to contact blood from a bleeding wound;

wherein the substrate initially exists separately from the hemostatic material;

wherein the hemostatic device is configured so that the hemostatic material does not substantially detach from the substrate before use;

wherein the device is configured such that when the blood from the bleeding wound contacts the substrate, the blood interacts with at least some of the hemostatic aluminum silicate material on the substrate, which assists in accelerating clotting; and

wherein the hemostatic aluminum silicate is not a zeolite.

2. The hemostatic device of claim 1 , wherein the hemostatic aluminum silicate material is a clay material.

3. The hemostatic device of claim 2 , wherein the clay material is kaolin.

4. The hemostatic device of claim 1 , wherein the hemostatic material is bound to the substrate using a binder selected from the group consisting of chitosan, polyvinyl alcohol, guar gum, gelatinized starches, polysaccharides, cellulose, calcium alginate, and glycerol.

5. The hemostatic device of claim 1 , wherein the hemostatic material is bound to the substrate using a glycerol binder.

6. The hemostatic device of claim 1 , wherein the hemostatic device is subjected to a drying process during manufacturing.

7. The hemostatic device of claim 1 , wherein the hemostatic device further comprises an additional hemostatic aluminum silicate material.

8. The hemostatic device of claim 1 , wherein the hemostatic device is provided in a sealed sterilized package prior to use.

9. The hemostatic device of claim 8 , wherein the hemostatic device is not saturated with a liquid when in the sterilized package.

10. A hemostatic device comprising:

a flexible absorbent substrate;

a hemostatic material positioned on or in the substrate in a region configured to contact blood from the bleeding wound during use, the hemostatic material comprising an aluminum silicate;

wherein the substrate initially exists separately from the hemostatic material;

wherein the hemostatic material is adhered to the substrate and is configured to substantially remain on or in the substrate before use; and

wherein the device is configured such that when the blood contacts the substrate, it interacts with at least some of the hemostatic material on the substrate, which assists in accelerating clotting and does not produce heat;

wherein the device is subjected to a drying process during manufacturing.

11. The hemostatic device of claim 10 , wherein the hemostatic material is made at least in part by heating kaolin or kaolinite and forming a vitrified or glassy material.

12. The hemostatic device of claim 10 , wherein the hemostatic material is applied to the substrate as a slurry comprising water and a binder.

13. The hemostatic device of claim 12 , wherein the binder is selected from the group consisting of chitosan, polyvinyl alcohol, guar gum, gelatinized starches, polysaccharides, cellulose, and calcium alginate.

14. The hemostatic device of claim 13 , wherein the hemostatic material comprises clay.

15. The hemostatic device of claim 13 , wherein the hemostatic material comprises kaolin or kaolinite.

16. The hemostatic device of claim 12 , wherein the binder is glycerol.

17. The hemostatic device of claim 16 , wherein the hemostatic material comprises clay.

18. The hemostatic device of claim 16 , wherein the hemostatic material comprises kaolin or kaolinite.

19. The hemostatic device of claim 10 , wherein the hemostatic device comprises carboxymethylcellulose.

20. The hemostatic device of claim 19 , wherein the hemostatic material comprises clay.

21. The hemostatic device of claim 19 , wherein the hemostatic material comprises kaolin or kaolinite.

22. The hemostatic device of claim 10 , wherein the hemostatic device further comprises an additional hemostatic aluminum silicate material.

Assignments (8)
SECURITY INTEREST Recorded Mar 1, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066723/0376 →
CHANGE OF NAME Recorded Feb 29, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066836/0737 →
MERGER Recorded Feb 29, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066707/0695 →
MERGER Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES II LLC
To: TELEFLEX TECHNOLOGIES LLC
Reel/Frame 066621/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066616/0701 →
CHANGE OF NAME Recorded Feb 16, 2024
From: TELEFLEX TECHNOLOGIES LLC
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066621/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: TELEFLEX LIFE SCIENCES LIMITED
To: TELEFLEX LIFE SCIENCES II LLC
Reel/Frame 066434/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: Z-MEDICA, LLC
To: TELEFLEX LIFE SCIENCES LIMITED
Reel/Frame 058740/0387 →
Continuity (13)
Continuation 17178047 · Feb 17, 2021
Continuation 15841843 · Dec 14, 2017
Continuation 15090072 · Apr 4, 2016
Continuation 14185873 · Feb 20, 2014
Continuation 13759963 · Feb 5, 2013
Continuation 13682085 · Nov 20, 2012
Continuation 13363270 · Jan 31, 2012
Continuation 12581782 · Oct 19, 2009
Continuation 11715057 · Mar 6, 2007
Continuation In Part 11590427 · Oct 30, 2006
Provisional Application 60810447 · Jun 1, 2006
Provisional Application 60808618 · May 26, 2006
Related Publication 20210379238A1 · Dec 9, 2021
Cited By (1)
US 12,685,799